Chief and be our a than Officer. Thank bit Kim you, joined by remarks morning, longer good operator, My I'm prepared everyone. today Peery, Financial will today normal.
and on our of our to annual to Stereotaxis, use our impactful I context technology results, as highly then the occasion a key well As will as the for review path coming expectations recent provide building call I the broader company. and year. goals our
pioneer Stereotaxis endovascular of and for robotics leader is the surgery.
the catheters. risks manual have posed by challenges inherent limitations, innovative developed that We an handheld and suite of address technologies
mission of make to to with its safety more invasive modernize and outcomes surgery digitization the robotics. improve endovascular it is Our to and and benefits broadly available minimally
Endovascular are of surgery procedures millions is a with small of catheters system. action manual as patients through the positively handheld patient's navigated interventional flaws. fundamental Endovascular impact of annually field vascular where medicine of a mechanism broad and growing devices
is to of any the feet visualization X-ray Procedures physicians reach. tip, be like are therapy and limited is the place for During not not and manual exposes operator to the control and manipulated Is dependent pencil precise, catheter from tip, a of patients the to risk Manual away stable catheters holding patient complex need increasing there radiation. and allow a of and at injury. takes a but rigid catheter at procedure, the It's held several catheter handle. its eraser.
precise Physicians our allowing inherent unreachable enables challenges precision computer controlled physician areas with addresses safety. endovascular radiation patient aspects computer and profession. an unpresidented patients with as from and and cognitive enhances catheter robot technology XXX scientific seated using treated stability, focus hospitals magnetic the documenting upgrade XXX,XXX for tip robotic of These technology a traditional limitations, surgery to with This XXX and cockpit, for procedure and hundreds fields. of and control over a allows direct not by the reaching Stereotaxis’s from of their risks and our over ability protected benefits there our have are nearly globally theoretical, on publications full the control at value. previously physicians leading are clinical over of
which of that technology in surgical robotics serves platform preeminent clinical confers to build field large as a differentiated highly foundation company. perfect A medicine value a on meaningful the
a to flourishing the of transforming clear laparoscopic clinical are commercial best But suited while a We and see path how been fashion in a to ability business our validation, field surgery grow has are surgeries by similar has being and transformed. orthopedic positively limitations. the our constrained technology and structural towards significant endovascular broad several
clear these challenges on on are to We addressing the them. eyed way and well
Our product structural three limitations. ecosystem primary has
be construction contractors, pipeline. and robotic done planning. adopted to It multiyear sales if with of system sales only and process. attrition a part obviously architects is It be the in modifications leads our First, can room as and significant significant significant effort requires cycles can
another EP ablation built to confirming arrhythmias, field. dependencies is treat existing significant significant differentiated with robotic procedures sophisticated, cardiac procedural our benefits heart and on technology the Second, focus, was Stereotaxis’s highly company. in
by used and actual owned, is company. However, sold another manufactured procedure in ablation catheter every the
to our customers, that Our various led challenges largely users extended on dependency creates were mapping limited for dependent also diagnostic innovation That and hurdles of periods and Stereotaxis. for technology. strategic operational, made creates financial company's
the the tools broader application company robot even reality. applications has a our serve neuro, endovascular the platform our ability technology. This opportunity is to made turn regulatory scope remained limited a technology purchasers. limitation coronary surgery, into structural the last and and having clearances the and to surgery Despite Stereotaxis’s single for has of reduces as clinical a market Third, robotic that, the the to and not interventional attraction peripheral like technology potential hospital
allows clear a focus. strategic focus, each A easily we elegant addresses or developed effort of limitations. not and regulated involving have advanced that for highly environment limitations sophisticated eye strategy rapidly. significant done multiple addressing these technologies Simultaneously diagnosis With and is an creativity in structural complex
address transformation ecosystem that poised limitations commercial an strategic expect achieve several be year, been we a these energetically This of to For us technologies make major we've years product to reality. to XXXX, as multiple now, working exciting of and milestones. is each that our for year regulatory
field. expected me ablation improves of users and ago. were with for MAGiC robotically-navigated along submit progress call closest the timeline of Mark MAGiC upon We proprietary strategic aging to European the It new addresses cornerstones are line summer same review limited last and operational, status posed Stereotaxis’s each. catheter ecosystem the financial by shared in in with challenges the catheter commercialization. pleased year is EP that a dependency Let technology we the our current product our the the to this to CE on and
the the technical, In regulator. passed categories; you receiving We three received step us early the microbiology. submission and our involves this next them technical that responded to in on clinical review in fourth questions distinct submission we the EU check December our and The completeness year. of process questions updated quarter, successfully in the
preparing technical them feedback un-concerning. our yet a We are received have days any clinical just as questions on We not the view response, the reviewing two but response. and questions received and ago
have receive far to received eager but so them. questions, are not the We microbiology
frustrating of is of technology, outside the to ultimately regulatory timeline review that The is we launch process but slow control. as are our pace the eager
speed responding We will this part questions do to our and rapidly thoughtfully. to by process
robust this to time use the will for set We stage commercialization.
substantial expect interest impact the in and start a as excited There's from likely the most of the launch to MAGiC second MAGiC occur we're the physician launch. Mark CE and in or customers our European for We summertime. to quarter of using later
our and GLP ensure care done November the we internal well. official use U.S. few submission but pilot We dependent quality processes several a new successfully of in a on studies the successfully that and will studies. establishing to In the was it this have institutional and The development significant our studies remains program survival of animal pivotal completing undertaking, IDE preclinical ran and infrastructure an worked record weekend. and facility on capability do level first
human the end. the pivotal expect We in trial before our application complete submit third the all to the in second quarter, initiate IDE studies quarter IDE year and FDA to
years MAGiC reasonable timer. a to Mark two catheter U.S. as continue see after We CE of FDA approval the approximately
makes navigate a try Our us robotic is were accessible to planning currently second innovation architectural that it, self-shielding our physicians effort frees and adopt construction hurdles. major many to robot and economic more technology. adopt unable extensive that and but It smaller from to or have the customers to technology our necessary logistic wanted the
We advancing methodically are line software through in the mechanical shared and electrical timelines. development with previously and
in launch the in clearance the of U.S. the an in this in Europe broader regulatory regulatory new third both with and the year, of quarter system a Europe robot initial approval that of and expect We concurrent XXXX. limited launch
innovation technology what sales is efforts technological integration advantage with for transformative be that itself our take possible. of will also and site assessment, we this to full of innovation, and Stereotaxis now along robot innovating is The the a accessibility our installation,
we guidewires previously of and we're is that our anatomy catheters Our challenging new of We've tortuous is specific endovascular can patient a third the family robot indications significant guide specific -- benefits innovation improve interventional navigating believe care. five and into expand indications. shared clinical we
aortic grafts. embolization interventions, Neuro intervention, aneurysm coronary abdominal angioplasty, peripheral and tumor
begin first the U.S. effort end. this The family for submissions that end is manufacturing to of able testing that with we guidewire be the and grinding the This we is have improving process will few nearing review fully designed product within XXX(k) been the year months, and a next timeline. of believe and are through relatively a We regulatory the Europe process. formal in in streamlined regulatory we allowing before
wires this advance expect guide family Behind guidewire, and broader we catheters steadily first to a to market. of
the the our with clinical prominent strategy Once have innovation serious share to guidewire capable in of addressing in in allow we medical these excited we several submission multiple unmet devices we and an date conditions first view host several Their made will as for practical by these regulatory shared and physicians technology a have what are building experience. We their specialties. needs. very and perspective
mobile the earlier. These response and three catheter, endovascular limitations MAGiC described robot devices innovations, the strategic newer three our are structural to
and each them of to regulatory growing significant with milestones reaching next of year. commercial this have impact year commercial We line sight
to MicroPort connectivity. are three entered product room a In big digital are synergistic core strategic nurture ecosystem these developing into that growth additional fortunate drivers a for effort. internally two to were we our additive we specific China, China operating to broad strategic and platform and a opportunistic collaboration innovation we Beyond EP innovations, establish
submissions. approval Genesis and and has for submitted efforts preparing last have testing integrate regulatory to their additional and that MicroPort parallel, NMPA on submission. near the system are supplement been for mapping working our Chinese In completed to an documentation software term some and catheter year they with robots late additional MAGiC ablation
infrastructure China's now extended sales seen are half market XXXX. be to in capital in and They in have of in we ecosystem of launch expect future a first a year they on pipeline review the training at whole anticipation engaged see lines available commercial we and from customers. NMPA, product time a approximately now the team, Given of this that already investing
after We into commercial translating robust impressed launch soon gains ecosystem are clearance. anticipated and preparatory regulatory a Chinese efforts with these very that
a our initial [Sync] internally based external large version to simulate integrated called next release. connectivity Synchrony. a testing cloud both for platform and has connectivity called released generation been Sync an Our of a involves by display team app (ph)
solution sales will forces continue Synchrony model that physician sales to provide and for while medical quarter physicians ready display for release in will opportunity, next premium and coming broadly premium workflow, external available should screen to upfront environment. device app is track full the year. The on combination Synchrony be select weeks Sync enabling submission SaaS us refine in expect fourth and We for an subscriptions the operating such connectivity streamlined hospitals, and in it early The users. any large be regulatory a collaboration with the Sync with capital an attractive incremental summer. business of launch to The an in hardware is
as Each synergistic our independently growth complement and surgery transform also of these innovations endovascular as but drivers to serve as with robotics. they Collectively, our other. value product look being they ecosystem serve each existing advanced dwarfs we that substantial are individually business, core
these high the robotics company. preeminent technologies confident for are medical foundation serve high value growth, as We
will that transitory attempted revenue grow the infrastructure this growth, show with driving of become be three can larger in an to we to and While primary self-sufficient. needed restart years multiyear magnitude order transformation, goals, navigate place put strategic we've financially that the
made Overall, we have significant progress here.
was well So enhances the the and our many an as last us From prudent perspective, was and and processes manufacturing robust years. that the to challenges year and a serve into anticipate. continued and for systems, was in year highlight commercial capabilities. improve effort a infrastructure new growth but across other IT the we of aspects It built refine the well custom It will operations, significant company, facility. facilitates last including We've demonstrate quality our financially moving our headquarters results navigating expense path. infrastructure of
was XXXX Revenue in more challenged.
revenue were hospitals XXXX, disappointed the lower stable a reduce slight restart attributed attractive were we undergo revenue of a XXXX. able with during by growth revenue procedures to in we China and service approach or COVID various remained reported and On lockdown demonstrate significant capital meaningful in Recurring decline replacement cycles. revenue to the as predominantly relatively and heels sales, in when
XXXX, making ship reported to reflective efforts. demonstrated System systems nor activity. some meaningfully has our of of recognized year. delays not recognized was can over eight for and on systems. the a sales, million revenue, construction In $XX.X progress store previous we the for XXXX ways, million in purchase years seven XXXX, Three year. install after sold entering restart sales In however, received orders five the we slight as orders We is out revenue. $XX in Stereotaxis revenue, minimal actual down have have that on systems, it orders recognized our from year backlog many can hospital increase capital however, we of orders for only that been greenfield the not of system context systems came when capital revenue the those were We timelines revenue four compared capital United robotic pushed in systems XXXX. of That In have driven this been as for and States.
look overall revenue an XXXX, of As supports digit double growth. at we this backlog expectation
flow cash of inventory. utilization new beyond quarter, inventory on robot despite substantial XXXX, watermark million XXXX to million as through cash Financially, the eight $X approximately of In recognize departure that grow a to was several as our substantial a system year cash those per in expect in to about well on of headquarters, the backlog. our correspond of From cash the from revenue that that robots maintaining cash new with orders, above as financial spending just continue and portion majority were with year. free was high increased double a was utilization to About utilization half from posture. able the XXXX last $XX as near spending maintain for expect orders a We low use very years XXXX, of investments approximately of inflows for breakeven would the we R&D. well
start We and debt. million history given cash with is of of a approximately That our balance comforting XXXX $XX sheet no financial and prudence. strong
the We facility a with a spending XXXX counteracting and revenue lack purchasing XXXX tapering royalty rate spending lack increased on lower new income. and expect of burn growth, R&D overall compared to a of inventory in
allowing comfortable to ecosystem profitability. balance are us fund to bring and We carry to to sheet, with market, Stereotaxis transformative of commercialization our product that ecosystem our to
I results well will financial Kim to some provide few on now make and as opening our a the commentary call financial then Q&A. before comments will
